Nasim Ali

902 total citations · 1 hit paper
10 papers, 408 citations indexed

About

Nasim Ali is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Nasim Ali has authored 10 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Cardiology and Cardiovascular Medicine and 6 papers in Oncology. Recurrent topics in Nasim Ali's work include Sarcoma Diagnosis and Treatment (8 papers), Cardiac tumors and thrombi (6 papers) and Vascular Tumors and Angiosarcomas (4 papers). Nasim Ali is often cited by papers focused on Sarcoma Diagnosis and Treatment (8 papers), Cardiac tumors and thrombi (6 papers) and Vascular Tumors and Angiosarcomas (4 papers). Nasim Ali collaborates with scholars based in United Kingdom, France and Italy. Nasim Ali's co-authors include Charlotte Benson, Penella J. Woll, Christian Rothermundt, Sandra J. Strauss, Sandy Beare, Stephen Nash, Fiona Cowie, Roberto Tirabosco, Gareth J. Veal and Sharon Forsyth and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Nasim Ali

10 papers receiving 406 citations

Hit Papers

Gemcitabine and docetaxel versus doxorubicin as first-lin... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
    2017 340 citations Beatrice Seddon, Sandra J. Strauss et al. The Lancet Oncology profile →

Peers

Nasim Ali
Kathleen Polson United States
L Švancárová Denmark
P. Chalabreysse France
C. Piovesan Italy
E. Stoeckle France
Jean Jacques Michels France
Davis X. Yao United States
Gauri Bhuchar United States
M. M. Van Glabbeke Netherlands
Axelle Nzokirantevye Belgium
Kathleen Polson United States
Nasim Ali
Citations per year, relative to Nasim Ali Nasim Ali (= 1×) peers Kathleen Polson

Countries citing papers authored by Nasim Ali

Since Specialization
Citations

This map shows the geographic impact of Nasim Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nasim Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nasim Ali more than expected).

Fields of papers citing papers by Nasim Ali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nasim Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nasim Ali. The network helps show where Nasim Ali may publish in the future.

Co-authorship network of co-authors of Nasim Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Nasim Ali. A scholar is included among the top collaborators of Nasim Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nasim Ali. Nasim Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Woll, Penella J., Piers Gaunt, Charlotte Gaskell, et al.. (2023). Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata. British Journal of Cancer. 129(9). 1490–1499. 5 indexed citations
2.
Gent, David, Nasim Ali, Anna Olsson‐Brown, et al.. (2022). Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights. SHILAP Revista de lepidopterología. 15(3). 950–959. 2 indexed citations
3.
Sanfilippo, Roberta, Richard L. Hayward, Jammbe Musoro, et al.. (2022). Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma. JAMA Oncology. 8(10). 1420–1420. 3 indexed citations
4.
Sanfilippo, Roberta, Richard L. Hayward, Jammbe Musoro, et al.. (2021). Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.. Journal of Clinical Oncology. 39(15_suppl). 11518–11518. 3 indexed citations
5.
Gennatas, Spyridon, Florence Chamberlain, Thomas Carter, et al.. (2020). Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. PubMed. 10(1). 9–9. 4 indexed citations
6.
Schöffski, Patrick, Olivier Mir, Bernd Kasper, et al.. (2019). Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.. Journal of Clinical Oncology. 37(15_suppl). 11006–11006. 10 indexed citations
7.
Kalaiselvan, R, Kaitlyn Wong, Nasim Ali, et al.. (2018). Impact of centralization of services on outcomes in a rare tumour: Retroperitoneal sarcomas. European Journal of Surgical Oncology. 45(2). 249–253. 17 indexed citations
8.
Seddon, Beatrice, Sandra J. Strauss, Jeremy Whelan, et al.. (2017). Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. The Lancet Oncology. 18(10). 1397–1410. 340 indexed citations breakdown →
9.
Ferrari, Stefano, Paolo G. Casali, Jean‐Yves Blay, et al.. (2013). Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS).. Journal of Clinical Oncology. 31(15_suppl). 10568–10568. 3 indexed citations
10.
LaChance, Jenny, et al.. (2011). The Utility of PEG3350 without Electrolytes for 2-Day Colonoscopy Preparation in Children. European Journal of Pediatric Surgery. 21(5). 318–321. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathleen Polson Breakdown of academic impact, for papers by L Švancárová Breakdown of academic impact, for papers by P. Chalabreysse Breakdown of academic impact, for papers by C. Piovesan Breakdown of academic impact, for papers by E. Stoeckle Breakdown of academic impact, for papers by Jean Jacques Michels Breakdown of academic impact, for papers by Davis X. Yao Breakdown of academic impact, for papers by Gauri Bhuchar Breakdown of academic impact, for papers by M. M. Van Glabbeke Breakdown of academic impact, for papers by Axelle Nzokirantevye
Rankless by CCL
2026